A Phase 2 interventional study of Amiodarone Hydrochloride and Saline in Atrial Fibrillation and Esophageal Carcinoma, sponsored by OHSU Knight Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by OHSU Knight Cancer Institute · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing amiodarone in Atrial Fibrillation — 12 open to participants now, 12 under way, 3 of them phase 3. Amiodarone · Atrial Fibrillation.
Among the 46 studies testing amiodarone in Atrial Fibrillation, this one is the 30th largest by planned enrollment, is one of 6 that started in 2024, is one of 2 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 38th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →12 of the 46 studies testing amiodarone in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18+
Assiut University · Sites in Egypt
Ages 20–70 · Healthy volunteers
Population Health Research Institute · Sites in Canada
Ages 18+
Hippocration General Hospital · Sites in Greece
Ages 18–85
Stanford University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Amiodarone: first FDA approval 1985 (CORDARONE). What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 13 · Phase 4 20
First in 1998; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 124 across the 46 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 46 has an industry lead sponsor. The 10 most frequent:
OHSU Knight Cancer Institute is the lead sponsor of 243 studies on the registry; 42 are open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 15 (56%) have results posted.
OHSU Knight Cancer Institute has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
2 of the studies testing amiodarone in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07487714Tomsk National Research Medical Center of the Russian Academy of SciencesComparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration | 2027-05 |
| NCT06067438OHSU Knight Cancer InstituteAmiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | 2027-08-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing amiodarone in Atrial Fibrillation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients to receive preventative amiodarone or not. Further, there is no standard recommendation or guideline for preventative medications, such as amiodarone, to decrease the risk of AF in patients having MIE performed for cancer. In fact, most medical centers in the United States and around the world do not give preventative amiodarone after esophagectomy. Giving amiodarone after MIE surgery may be able to reduce the risk of AF for patients with esophageal cancer.
PRIMARY OBJECTIVE:
I. To evaluate the effect of prophylactic amiodarone on the rate of atrial fibrillation (AF) in patients undergoing minimally invasive esophagectomy (MIE).
SECONDARY OBJECTIVES:
I. In each subobjective, below, evaluations of the effects of prophylactic amiodarone on the following will be made:
Il. Evaluating the association between therapeutic (or serum levels and the development of AF in the experimental group only.
EXPLORATORY OBJECTIVE:
I. To evaluate the effect of prophylactic amiodarone administration on hospital cost of care.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive amiodarone hydrochloride intravenously (IV) for 4 days and then via a feeding tube for 3 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo (normal saline) IV for 4 days in the absence of disease progression or unacceptable toxicity.
Patients are followed for 60 days following discharge from hospitalization after MIE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients undergoing MIE will be evaluated for potential enrollment
Exclusion Criteria:
Pregnancy
(Fridericia formula) > 500 for heart rate (HR) 60-100 within 30 days
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive amiodarone hydrochloride IV for 4 days and then via a feeding tube for 3 days on study.
Drug: Amiodarone Hydrochloride
Patients receive normal saline IV for 4 days on study.
Other: Saline
Given IV and via feeding tube
Also known as: Cordarone, Nexterone
Given IV
Also known as: ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%
Development of atrial fibrillation (AF), or completion of seven-day course of amiodarone
Will be a binary variable (yes/no) and analyzed using a one-sided test of two proportions at an alpha level of 0.05.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 7, after last dose of enteral amiodarone
Postoperative (PostOp) rapid ventricular response
Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% confidence interval (CI) of the difference between the two proportions.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to discharge (DC) from hospital.
Postop pulmonary complications
Including pneumonia, acute respiratory distress syndrome, acute pulmonary edema, and chylothorax. Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30
Anastomotic leak
Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30
ICU Readmission
Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30
ICU length of stay (LOS)
Will be assessed in days. Analysis: Wilcoxon rank sum test
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to time patient is moved out of ICU
Hospital LOS
Will be assessed in days. Analysis: Wilcoxon rank sum test
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to time of discharge from hospital
30 Day readmission rate
Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.
Time frame: Day of discharge (DC) from hospital to 30 days after discharge
Inpatient morality
Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to time of discharge from hospital
Incidence of mortality within 30 days of surgery
Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30
Incidence and type of adverse events
Will be a binary value (yes/no). Analysis: Binomial test; point estimate and 95% CI of the difference between the two proportions.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 30
Time to AF
Analysis: Log-rank test.
Time frame: From initiation of amiodarone in the intensive care unit (ICU) to post-operative day (POD) 7
Serum amiodarone level, classified as therapeutic or subtherapeutic
Time frame: Post-operative day (POD) 2 to post-operative day (POD) 3
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.
Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 38 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amiodarone
OHSU Knight Cancer Institute →